Disease · MONDO_0005706
coccidioidomycosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. coccidioidomycosis. Diseases, record MONDO_0005706. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005706
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
California disease, Coccidioides immitis caused disease or disorder, Coccidioides immitis disease or disorder, Coccidioides immitis infectious disease, Coccidioides infection, San Joaquin valley fever, Valley fever, desert fever, desert rheumatism, primary extrapulmonary coccidioidomycosis, primary extrapulmonary coccidioidomycosis (disorder)
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| POSACONAZOLE | CHEMBL1397 | Small molecule | Approval | EMA Human Drugs and PMDA | 4 | 1 | 1 | Drugs and targets |
| FLUCONAZOLE | CHEMBL106 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ITRACONAZOLE | CHEMBL64391 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIKKOMYCIN | CHEMBL35306 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VT-1598 | CHEMBL4594426 | Small molecule | Phase 1 | TTD | 1 | 0 | 0 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | 1 | Serotonin transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6532 |
Source Drugs and targets
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03572049 | Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole | Phase 2/3 | 88 | 2022-10-06 | Invasive Fungal Infections | ITRACONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00423267 | POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) | Phase 3 | 16 | 2010-06-30 | Coccidioidomycosis | FLUCONAZOLE, POSACONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00614666 | Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment | Phase 1/2 | 6 | 2025-04-16 | Coccidioidomycosis | NIKKOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02908334 | Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis | Phase 2 | 0 | Coccidioidomycosis | SERTRALINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04809649 | SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole | Phase 2 | 0 | Coccidioidomycosis, Valley Fever | ITRACONAZOLE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SUBA Itraconazole vs Conventional Itraconazole: deaths from any cause | 1 of 42 | 0 of 46 | 88 | NCT03572049 | Trial comparisons |
| SUBA Itraconazole vs Conventional Itraconazole: serious adverse events | 4 of 42 | 12 of 46 | 88 | NCT03572049 | Trial comparisons |
| SUBA Itraconazole vs Conventional Itraconazole: Resolution of Signs and Symptoms of Invasive Fungal Infection on Day 42 | 29 of 37 | 30 of 40 | 77 | NCT03572049 | Trial comparisons |
| Posaconazole vs Fluconazole: Number of Participants With Treatment-emergent Adverse Events (TEAEs)That Occurred With POS or FLU in Period A | 8 of 9 | 5 of 7 | 16 | NCT00423267 | Trial comparisons |
| Posaconazole vs Fluconazole: Number of Participant Discontinuations Due to Adverse Events and/or Laboratory Evaluations of Safety in Period A | 0 of 9 | 0 of 7 | 16 | NCT00423267 | Trial comparisons |
| Posaconazole vs Fluconazole: Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A | 5 of 9 | 3 of 7 | 16 | NCT00423267 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005706
GET https://conductscience.org/api/diseases/v1/MONDO_0005706/drugs